Related Posts
Any trans in this bowl from India ?
when Work >>> Life 😅

Additional Posts in Pharma and Biotech
Johnson & Johnson Is there any news on pharma giant layoffs and freeze-hiring? AbbVie Biogen Bristol Myers Squibb Eli Lilly and Company Gilead Sciences Johnson & Johnson Intellia Therapeutics, Inc Pfizer Novo Nordisk Merck Roche Regeneron Merck Teva Pharmaceuticals
New to Fishbowl?
unlock all discussions on Fishbowl.




Thank you SD, you’ve been posting some excellent insights and I really appreciate it.
Mentor
You are welcome BCG1! Happy to help and share the knowledge!
Mentor
TL;DR:
At JPM 2025, Takeda emphasized its strategic shift towards four core R&D modalities (small molecules, biologics, antibody-drug conjugates, and allogeneic cell therapies) and three therapeutic areas (oncology, neuroscience, and GI-squared). The company highlighted six key pipeline assets with peak sales potential of $10–20B, addressing unmet needs in rare and prevalent diseases. A disciplined investment approach focuses on late-stage assets and option-based licensing deals, exemplified by the $200M Keros Therapeutics deal for elritercept. Takeda leverages innovation with AI and digital tools to enhance patient outcomes, setting the stage for growth despite upcoming challenges like Entyvio biosimilar competition.